TW224055B - - Google Patents
Info
- Publication number
- TW224055B TW224055B TW082107064A TW82107064A TW224055B TW 224055 B TW224055 B TW 224055B TW 082107064 A TW082107064 A TW 082107064A TW 82107064 A TW82107064 A TW 82107064A TW 224055 B TW224055 B TW 224055B
- Authority
- TW
- Taiwan
- Prior art keywords
- sustained
- novel compositions
- release
- bioactive
- novel
- Prior art date
Links
- 230000000975 bioactive effect Effects 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 abstract 2
- 102000018997 Growth Hormone Human genes 0.000 abstract 1
- 108010051696 Growth Hormone Proteins 0.000 abstract 1
- 102000038461 Growth Hormone-Releasing Hormone Human genes 0.000 abstract 1
- 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 abstract 1
- 239000002202 Polyethylene glycol Substances 0.000 abstract 1
- 101710142969 Somatoliberin Proteins 0.000 abstract 1
- 235000013773 glyceryl triacetate Nutrition 0.000 abstract 1
- 239000001087 glyceryl triacetate Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229920001223 polyethylene glycol Polymers 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
- 239000000725 suspension Substances 0.000 abstract 1
- 230000002459 sustained effect Effects 0.000 abstract 1
- 238000013268 sustained release Methods 0.000 abstract 1
- 239000012730 sustained-release form Substances 0.000 abstract 1
- 229960002622 triacetin Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Immunology (AREA)
- Pregnancy & Childbirth (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Reproductive Health (AREA)
- Organic Chemistry (AREA)
- Gynecology & Obstetrics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US94787292A | 1992-09-21 | 1992-09-21 | |
US96336592A | 1992-10-20 | 1992-10-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
TW224055B true TW224055B (zh) | 1994-05-21 |
Family
ID=27130263
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW082107064A TW224055B (zh) | 1992-09-21 | 1993-08-31 |
Country Status (12)
Country | Link |
---|---|
US (1) | US6011011A (zh) |
EP (1) | EP0661989B1 (zh) |
JP (2) | JP3756512B2 (zh) |
AT (1) | ATE156361T1 (zh) |
AU (1) | AU5018693A (zh) |
DE (1) | DE69312947T2 (zh) |
DK (1) | DK0661989T3 (zh) |
ES (1) | ES2107051T3 (zh) |
GR (1) | GR3024632T3 (zh) |
MX (1) | MX9305729A (zh) |
TW (1) | TW224055B (zh) |
WO (1) | WO1994006452A1 (zh) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6150330A (en) | 1996-01-11 | 2000-11-21 | Pharmacia & Upjohn Company | Aqueous prolonged release formulation |
US5932547A (en) * | 1996-07-03 | 1999-08-03 | Alza Corporation | Non-aqueous polar aprotic peptide formulations |
AU737664B2 (en) * | 1996-07-03 | 2001-08-30 | Alza Corporation | Non-aqueous protic peptide formulations |
KR100594519B1 (ko) * | 1996-07-03 | 2007-03-02 | 앨자 코포레이션 | 비수성양성자성펩티드제제 |
KR100593221B1 (ko) * | 1996-07-03 | 2007-03-02 | 알자 코포레이션 | 비수성극성비양성자성펩타이드제제 |
US5981489A (en) * | 1996-07-18 | 1999-11-09 | Alza Corporation | Non-aqueous protic peptide formulations |
IN184589B (zh) | 1996-10-16 | 2000-09-09 | Alza Corp | |
US7732404B2 (en) * | 1999-12-30 | 2010-06-08 | Dexcel Ltd | Pro-nanodispersion for the delivery of cyclosporin |
US6524580B1 (en) | 2000-02-15 | 2003-02-25 | Allergan Sales, Inc. | Method for treating thyroid disorders |
US6773711B2 (en) * | 2000-02-15 | 2004-08-10 | Allergan, Inc. | Botulinum toxin therapy for Hashimoto's thyroiditis |
US6358513B1 (en) | 2000-02-15 | 2002-03-19 | Allergan Sales, Inc. | Method for treating Hashimoto's thyroiditis |
US6649161B1 (en) | 2000-02-22 | 2003-11-18 | Allergan, Inc. | Method for treating hypocalcemia |
US20040170665A1 (en) * | 2000-06-02 | 2004-09-02 | Allergan, Inc. | Intravitreal botulinum toxin implant |
US6306423B1 (en) | 2000-06-02 | 2001-10-23 | Allergan Sales, Inc. | Neurotoxin implant |
US20040033241A1 (en) * | 2000-06-02 | 2004-02-19 | Allergan, Inc. | Controlled release botulinum toxin system |
EP1339312B1 (en) * | 2000-10-10 | 2006-01-04 | Microchips, Inc. | Microchip reservoir devices using wireless transmission of power and data |
KR100838219B1 (ko) * | 2001-07-13 | 2008-06-13 | 동아제약주식회사 | 인간성장호르몬의 지속적인 방출이 가능한 생분해성약학적 조성물 및 미립구 제형 |
WO2004022033A1 (en) * | 2002-09-04 | 2004-03-18 | Microchips, Inc. | Method and device for the controlled delivery of parathyroid hormone |
US7074425B2 (en) * | 2002-09-26 | 2006-07-11 | Bonewax, Llc | Hemostatic compositions and methods |
PT2891666T (pt) | 2002-10-16 | 2017-09-22 | Purdue Pharma Lp | Anticorpos que se ligam ca 125/0722p associado a células e métodos para a sua utilização |
US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
EP1663296A4 (en) * | 2003-09-25 | 2009-11-25 | Cangene Corp | LIQUID FORMULATION OF HUMAN GROWTH HORMONE CONTAINING POLYETHYLENE GLYCOL |
EP1682537B1 (en) | 2003-11-05 | 2012-03-28 | SARcode Bioscience Inc. | Modulators of cellular adhesion |
WO2006081279A2 (en) * | 2005-01-25 | 2006-08-03 | Microchips, Inc. | Control of drug release by transient modification of local microenvironments |
TW200640492A (en) | 2005-02-21 | 2006-12-01 | Lg Life Sciences Ltd | Sustained release composition of protein drug |
CA2610159C (en) * | 2005-06-10 | 2015-03-31 | Altus Pharmaceuticals Inc. | Methods to reduce oxalate concentration by administration of oxalate oxidase crystals |
US7756524B1 (en) | 2006-01-31 | 2010-07-13 | Nextel Communications Inc. | System and method for partially count-based allocation of vocoder resources |
US20070178138A1 (en) * | 2006-02-01 | 2007-08-02 | Allergan, Inc. | Biodegradable non-opthalmic implants and related methods |
MX354786B (es) | 2007-06-04 | 2018-03-21 | Synergy Pharmaceuticals Inc | Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos. |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
US20090155176A1 (en) | 2007-10-19 | 2009-06-18 | Sarcode Corporation | Compositions and methods for treatment of diabetic retinopathy |
PT2219603E (pt) | 2007-11-02 | 2014-09-02 | Acrux Dds Pty Ltd | Piperazinas como agentes antimalariais |
US9107815B2 (en) | 2008-02-22 | 2015-08-18 | Allergan, Inc. | Sustained release poloxamer containing pharmaceutical compositions |
EP2276508A4 (en) * | 2008-04-15 | 2011-12-28 | Sarcode Bioscience Inc | RELEASE OF LFA-1 ANTAGONISTS AGAINST THE GAS-DARM SYSTEM |
CA2726917C (en) | 2008-06-04 | 2018-06-26 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
WO2010009319A2 (en) | 2008-07-16 | 2010-01-21 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
WO2011060352A1 (en) * | 2009-11-16 | 2011-05-19 | Ipsen Pharma S.A.S. | Pharmaceutical compositions of melanocortin receptor ligands |
DE102009056745A1 (de) * | 2009-12-04 | 2011-06-09 | Lts Lohmann Therapie-Systeme Ag | Transdermales therapeutisches System für die Verabreichung von Peptiden |
CN107056929A (zh) * | 2009-12-21 | 2017-08-18 | Ambrx 公司 | 经过修饰的猪促生长素多肽和其用途 |
CN107674121A (zh) * | 2009-12-21 | 2018-02-09 | Ambrx 公司 | 经过修饰的牛促生长素多肽和其用途 |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
RU2768492C2 (ru) | 2011-11-18 | 2022-03-24 | Ридженерон Фармасьютикалз, Инк. | Полимерные белковые микрочастицы |
AR091784A1 (es) * | 2012-07-17 | 2015-02-25 | Bayer New Zealand Ltd | Formaciones inyectables de antibiotico y sus metodos de aplicacion |
US9545446B2 (en) | 2013-02-25 | 2017-01-17 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase and their uses |
WO2014151200A2 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
EP2970384A1 (en) | 2013-03-15 | 2016-01-20 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
US20160220630A1 (en) | 2013-10-10 | 2016-08-04 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of opioid induced dysfunctions |
AR101476A1 (es) | 2014-08-07 | 2016-12-21 | Acerta Pharma Bv | Métodos para tratar cánceres, enfermedades inmunes y autoinmunes, y enfermedades inflamatorias en base a la tasa de ocupación de la tirosin quinasa de bruton (btk) y a la tasa de resíntesis de la tirosin quinasa de bruton (btk) |
CN113827704B (zh) * | 2015-10-16 | 2024-07-12 | 瑞泽恩制药公司 | 稳定蛋白质组合物 |
US10653744B2 (en) | 2016-01-11 | 2020-05-19 | Bausch Health Ireland Limited | Formulations and methods for treating ulcerative colitis |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1185340A (en) * | 1967-12-19 | 1970-03-25 | Gen Foods Corp | Water Dispersable Hydrophilic Colloid Composition. |
US4041155A (en) * | 1974-10-29 | 1977-08-09 | American Home Products Corporation | Long acting somatostatin composition |
US3966962A (en) * | 1975-03-27 | 1976-06-29 | The Upjohn Company | Triacetin solutions of PGE-type compounds |
US4301175A (en) * | 1980-12-29 | 1981-11-17 | The Upjohn Company | E-Type prostaglandin compositions |
ZA831186B (en) * | 1982-03-22 | 1983-11-30 | Upjohn Ltd | Gelled pge2/triacetin solutions |
EP0140255B1 (en) * | 1983-10-14 | 1991-05-15 | Sumitomo Pharmaceuticals Company, Limited | Sustained-release injections |
JPS60224638A (ja) * | 1984-04-23 | 1985-11-09 | Kao Corp | 経皮吸収促進剤およびこれを含有する外用剤 |
ES8702440A1 (es) * | 1984-10-04 | 1986-12-16 | Monsanto Co | Un procedimiento para la preparacion de una composicion de polipeptido inyectable sustancialmente no acuosa. |
US4977140A (en) * | 1985-08-23 | 1990-12-11 | Eli Lilly And Company | Injectable sustained release formulation |
JPS62123112A (ja) * | 1985-11-22 | 1987-06-04 | Sunstar Inc | 軟膏基剤 |
US4917685A (en) * | 1986-05-16 | 1990-04-17 | International Minerals & Chem. Corp. | Delivery device for the administration of stabilized growth promoting hormones |
FR2606597B1 (fr) * | 1986-11-17 | 1989-01-27 | Rhone Poulenc Sante | Nouvelle composition pour l'alimentation des ruminants contenant une substance biologiquement active et sa preparation |
US4795641A (en) * | 1987-08-20 | 1989-01-03 | Eastman Kodak Company | Polymer blends having reverse phase morphology for controlled delivery of bioactive agents |
US5004728A (en) * | 1988-03-11 | 1991-04-02 | The Trustees Of The University Of Pennsylvania | Methods of increasing milk yields in ruminants |
IT1230576B (it) * | 1988-10-20 | 1991-10-28 | Angeli Inst Spa | Formulazioni farmaceutiche per via orale a liberazione selettiva nel colon |
DE59009781D1 (de) * | 1989-05-16 | 1995-11-23 | Puetter Medice Chem Pharm | Verfahren zur Herstellung optisch aktiver 2-Aryl-Alkansäuren, insbesondere von 2-Aryl-Propionsäuren. |
NZ234802A (en) * | 1989-08-14 | 1992-11-25 | Merck & Co Inc | Long acting injectable formulations comprising an avermectin compound and triacetin. treatment for internal and external parasites of animals |
US5179189A (en) * | 1990-01-19 | 1993-01-12 | Nova Pharmaceutical Corporation | Fatty acid terminated polyanhydrides |
EP0532546B1 (en) * | 1990-05-10 | 1998-03-18 | Bechgaard International Research And Development A/S | A pharmaceutical preparation containing n-glycofurols and n-ethylene glycols |
US5091185A (en) * | 1990-06-20 | 1992-02-25 | Monsanto Company | Coated veterinary implants |
US5206219A (en) * | 1991-11-25 | 1993-04-27 | Applied Analytical Industries, Inc. | Oral compositions of proteinaceous medicaments |
-
1993
- 1993-08-23 WO PCT/US1993/007756 patent/WO1994006452A1/en active IP Right Grant
- 1993-08-23 JP JP50808394A patent/JP3756512B2/ja not_active Expired - Fee Related
- 1993-08-23 AT AT93920157T patent/ATE156361T1/de not_active IP Right Cessation
- 1993-08-23 AU AU50186/93A patent/AU5018693A/en not_active Abandoned
- 1993-08-23 EP EP93920157A patent/EP0661989B1/en not_active Expired - Lifetime
- 1993-08-23 ES ES93920157T patent/ES2107051T3/es not_active Expired - Lifetime
- 1993-08-23 DE DE69312947T patent/DE69312947T2/de not_active Expired - Fee Related
- 1993-08-23 DK DK93920157.0T patent/DK0661989T3/da active
- 1993-08-31 TW TW082107064A patent/TW224055B/zh active
- 1993-09-20 MX MX9305729A patent/MX9305729A/es not_active IP Right Cessation
-
1995
- 1995-03-20 US US08/407,327 patent/US6011011A/en not_active Expired - Fee Related
-
1997
- 1997-09-04 GR GR970402270T patent/GR3024632T3/el unknown
-
2004
- 2004-07-13 JP JP2004206098A patent/JP2004285079A/ja not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
EP0661989B1 (en) | 1997-08-06 |
DK0661989T3 (da) | 1998-03-02 |
JP3756512B2 (ja) | 2006-03-15 |
JPH08501305A (ja) | 1996-02-13 |
JP2004285079A (ja) | 2004-10-14 |
AU5018693A (en) | 1994-04-12 |
ATE156361T1 (de) | 1997-08-15 |
MX9305729A (es) | 1994-03-31 |
EP0661989A1 (en) | 1995-07-12 |
ES2107051T3 (es) | 1997-11-16 |
US6011011A (en) | 2000-01-04 |
WO1994006452A1 (en) | 1994-03-31 |
GR3024632T3 (en) | 1997-12-31 |
DE69312947D1 (de) | 1997-09-11 |
DE69312947T2 (de) | 1998-01-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW224055B (zh) | ||
HK1021824A1 (en) | Compositions and methods for treating infections using analogues of indolicidin | |
EP1686172A3 (en) | Myocardial grafts and cellular compositions useful for same | |
NZ227788A (en) | Peptide having growth hormone regulatory effects, and compositions | |
EP1077070A3 (en) | Oral drug delivery compositions | |
ATE333464T1 (de) | Zusammensetzungen und verfahren zur behandlung von infektionen unter verwendung von kationischen peptiden allein oder in kombination mit antibiotika | |
NZ227787A (en) | Peptides and compositions having growth hormone regulatory effects | |
AU1750297A (en) | Humanized green fluorescent protein genes and methods | |
WO1994011503A3 (en) | Chimeric factor viii | |
EP1175909A8 (en) | Therapeutic methods and compositions based on serrate proteins and nucleic acids | |
AU575843B2 (en) | Growth hormone releasing peptides | |
WO2002058589A3 (en) | Agents and methods for promoting bone growth | |
HK1001207A1 (en) | Polypeptide compounds containing d-2-alkyltryptophan capable of promoting the release of growth hormone | |
CA2071757A1 (en) | Implant compositions containing a biologically active protein, peptide or polypeptide | |
IL95863A0 (en) | Anticoagulant peptides and compositions containing them | |
EP1174439A3 (en) | Compositions and methods for treating infections using analogues of indolicidin | |
JO1999B1 (en) | Isotopes of the hormone 'LH-RH' have their uses and the chemical compounds they contain | |
EP0723016A3 (en) | Leukocyte activation factor | |
WO2004089973A3 (en) | Peptides, polypeptides, and proteins of reduced immunogenicity and methods for their production | |
MX9604539A (es) | Aminoacidos modificados para la distribucion de farmaco. |